Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Aquilo Capital Management, LLC Buys Arvinas Inc, Dicerna Pharmaceuticals Inc, Regenxbio Inc, ...
07:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: DRNA , RGNX , ARWR , AMYT , ARVN , NGM , HARP , GLPG ,
REGENXBIO Inc. (NASDAQ:RGNX) Receives $58.25 Consensus Target Price from Brokerages
04:16pm, Tuesday, 16'th Nov 2021 Dakota Financial News
REGENXBIO Inc. (NASDAQ:RGNX) has been given a consensus recommendation of Buy by the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 []
Regenxbio (RGNX)'s Technical Outlook is Bright After Key Golden Cross
11:28am, Thursday, 04'th Nov 2021
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
REGENXBIO's (RGNX) CEO Ken Mills on Q3 2021 Results - Earnings Call Transcript
08:50pm, Tuesday, 02'nd Nov 2021
REGENXBIO's (RGNX) CEO Ken Mills on Q3 2021 Results - Earnings Call Transcript
Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect?
01:00pm, Tuesday, 02'nd Nov 2021
The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the posi
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
01:25pm, Monday, 11'th Oct 2021
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME). The data were
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observ
What's Next For REGENXBIO Stock After A 20% Fall Yesterday?
07:30am, Wednesday, 06'th Oct 2021
REGENXBIO stock declined by 20% yesterday, while it is down 26% in the last ten trading days. In comparison, the broader S&P500 index declined by 1.4% over the same period.
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events Positive initial data from Coho
REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
07:05am, Friday, 01'st Oct 2021
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presented REG
Regenxbio: Unlocking Value Through The Mega AbbVie Partnership
06:57pm, Monday, 27'th Sep 2021
The company recently inked a $1.7B deal with AbbVie for the development and commercialization of a potential mega-blockbuster, i.e., RGX-314. Under highly favorable deal terms, REGENXBIO will enjoy 50
REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
07:05am, Monday, 27'th Sep 2021
ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD (AAVIATE®) to be presented REGENXBIO
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
12:14pm, Tuesday, 14'th Sep 2021
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
12:14pm, Tuesday, 14'th Sep 2021
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?
09:10am, Tuesday, 14'th Sep 2021
REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
